Theralase Technologies Inc. V.TLT

RE:TLD-1433 Mentioned in new paper by European Researchers

[ScienceFirst]

Nice catch again Eoganacht.

We're seeing a growing number of references to our work and molecule in more and more research papers.  That's excellent and the only way to force the hand of big pharmas.

One day, we'll have them have more and more attention to how they can benefit PDT/PDC.  And TLT is clearly the most advanced, now 45% into a NMIBC ph. 2.  That's already worth close to 1B$ when you take a look at exemples like these:

 

Tag value, for 2-3% of NSCLC patients and only preclinical data;  500M$

 

Looking past Big Pharma rivals, Blueprint buys a preclinical biotech for $250M+

 

Nov. 29, 2021

 

J&J’s Rybrevant scored the first approval back in May for a small group of lung cancer patients with a rare EGFR mutation. Despite a swarm of other biopharma companies angling for a piece of that market, Blueprint Medicines is betting nearly $500 million on a candidate it thinks will stand out.

 

Blueprint is putting down $250 million in cash and another $215 million in biobucks for Lengo Therapeutics and its preclinical non-small cell lung cancer program LNG-451. Though it hasn’t been tested in humans, Blueprint says the candidate was “highly brain-penetrant” in preclinical trials, and has the potential to inhibit all common EGFR exon 20 insertion variants — which are found in just 2% to 3% of NSCLC patients.

 

 

4.1B$US for such a small market:

 

Repotrectinib is one of several molecules designed to treat cancers driven by ROS1-fusion mutations. Patients with ROS1 rearrangements, which are found in 1% to 2% of people with non-small cell lung cancer (NSCLC), are already served by Pfizer’s Xalkori and Roche’s Rozlytrek. Yet, Turning Point has spied an opportunity to muscle into the field and persuaded investors it has a shot at doing so.

 

Bristol Myers Squibb has nabbed Turning Point Therapeutics in a $4.1 billion buyout deal, just weeks after the biotech posted an upbeat round of positive human data for its lead drug, repotrectinib.

 

The buyout — at $76 a share — gives Bristol Myers a rival to Pfizer’s Xalkori and Roche’s Rozlytrek in ROS1-positive non-small cell lung cancer.

 

Bristol Myers to buy Turning Point Therapeutics for 4.1B$US

Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiates Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer (NSCLC); Expected to Launch in 2023

Bristol Myers Squibb to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of Turning Point Therapeutics for $76.00 per Share (4.1B$US)

 June 3 (Reuters) - Bristol Myers Squibb (BMY.N)said on Friday it would acquire drug developer Turning Point Therapeutics Inc (TPTX.O) for $4.1 billion in cash to gain access to a portfolio of promising cancer drugs.

The U.S. drugmaker will pay $76 per Turning Point share, a 122.5% premium to its last closing price.

Turning Point's lead asset is repotrectiniba that belongs to a class of treatments called tyrosine kinase inhibitors.